Angiopoietin-like 3

Angiopoietin-like 3 詳細

英語名Angiopoietin like 3市販薬剤の数1
治験薬の数14ターゲットの別称Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
研究&開発段階Approved
英語名Angiopoietin like 3
ターゲットの別称Angiopoietin Like 3,Angiopoietin 5,UNQ153/PRO179,Angiopoietin-5,Angiopoietin-like protein 3,ANGPT5,ANG-5,Angiopoietin-Related Protein 3,Angiopoietin-Like 3,FHBL2,ANL3,ANGPTL3
市販薬剤の数1
治験薬の数14
研究&開発段階Approved

Angiopoietin-like 3 製品リスト

  • 属性

    Protein (5)

  • 製品ライブラリ

    オンライン (5)

  • Human (4)Mouse (1)

  • タグ

    His Tag (3)His Tag & Avi Tag (1)Fc Tag (1)

  • マーカー

    Unconjugated (4)Biotin-labeled (1)

Angiopoietin-like 3バックグランド

Angiopoietin-like protein 3 (ANGPTL3) is also known as Angiopoietin-related protein 3, Angiopoietin-5 (ANGPT5 / ANG-5), is a member of the angiopoietin-like family of secreted factors. ANGPTL3 / ANGPT5 is predominantly expressed in the liver, and has the characteristic structure of angiopoietins, consisting of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain. The FBN-like domain in angiopoietin-like 3 protein was shown to bind alpha-5/beta-3 integrins, and this binding induced endothelial cell adhesion and migration. This protein may also play a role in the regulation of angiogenesis. Angptl3 also acts as dual inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL), and increases plasma triglyceride and HDL cholesterol in rodents. ANGPTL3 inhibit endothelial lipase to catalyze HDL-phospholipid and increase HDL-PL levels. Circulating PL-riched HDL particles have high cholesterol efflux abilities.

Angiopoietin-like 3分子の別称

ANGPTL3,ANGPT5,ANG-5,Angiopoietin-5,FHBL2

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
ZodasiranARO-ANG3; ARO-ANG33; VSA-003 (Arrowhead Pharmaceuticals)Phase 3 ClinicalRoche LtdDyslipidemias; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipoproteinemia Type II; Hypertriglyceridemia
詳細
LNA-043LNA-043Phase 2 ClinicalNovartis Pharma AgKnee Injuries; Osteoarthritis; Osteoarthritis, Knee
詳細
VupanorsenISIS-703802; PF-07285557Phase 2 ClinicalIonis Pharmaceuticals IncCardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Homozygous familial hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease
詳細
EDP-167EDP-167; EDP167Phase 2 ClinicalEteng Pharmaceutical (Zhuhai) Co LtdDyslipidemias; Homozygous familial hypercholesterolemia
詳細
ALN-ANG3ALN-ANG3Phase 2 ClinicalAlnylam Pharmaceuticals IncDiabetic Nephropathies
詳細
BW-00112BW-00112; BW00112Phase 2 ClinicalShanghai Argo Biopharmaceutical Co LtdDyslipidemias; Hypertriglyceridemia
詳細
SolbinsiranLY-3561774; DCR-CM-1; DCR-CM1Phase 2 ClinicalDicerna Pharmaceuticals IncCardiovascular Diseases; Dyslipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases
詳細
JS-401JS-401; RP-912Phase 1 ClinicalRisen (Suzhou) Pharma Tech Co LtdHyperlipidemias; Metabolic Diseases
詳細
VERVE-201VERVE-201Phase 1 ClinicalBroad Institute, Harvard UniversityAtherosclerosis; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia
詳細
SYH-2070SYH2070; SYH-2070Phase 1 ClinicalCspc Heibei Zhongrun Pharmaceutiacl Co LtdHyperlipidemia, Familial Combined; Hyperlipidemias; Hypertriglyceridemia
詳細
NN-6491NN6491; NN-6491Phase 1 ClinicalNovo Nordisk A/SCardiovascular Diseases
詳細
NNC0491-6075NNC0491-6075; NNC04916075Phase 1 ClinicalNovo Nordisk A/SDyslipidemias
詳細
AZD-1705AZD1705; AZD-1705Phase 1 ClinicalAstrazeneca Plc, Parexel International CorpCardiovascular Diseases
詳細
CTX-310CTX-310; CTX310Phase 1 ClinicalCrispr Therapeutics AgCardiovascular Diseases; Dyslipidemias; Heterozygous familial hypercholesterolemia; Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lipid Metabolism Disorders; Metabolic Diseases; Sitosterolemia
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
EvinacumabREGN-1500ApprovedRegeneron Pharmaceuticals IncEvkeezaUnited StatesHypercholesterolemia; Homozygous familial hypercholesterolemiaRegeneron Pharmaceuticals Inc2021-02-11Homozygous familial hypercholesterolemia; Hypercholesterolemia; Hypertriglyceridemia; Metabolic Diseases
詳細
  • 詳細
  • 製品リスト
  • 市販薬剤に関する情報
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8